• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function.帕立普瑞韦/利托那韦、奥比他韦和达沙布韦治疗不同肾功能水平丙型肝炎病毒感染的安全性和有效性
Kidney Int Rep. 2018 Dec 1;4(2):191-193. doi: 10.1016/j.ekir.2018.11.018. eCollection 2019 Feb.
2
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.用于丙型肝炎病毒1型感染的奥比他韦/帕利哌韦/利托那韦和达沙布韦片
Ann Pharmacother. 2015 May;49(5):566-81. doi: 10.1177/1060028015570729. Epub 2015 Feb 13.
3
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.帕利瑞韦/利托那韦、奥比他韦、达沙布韦联合治疗肝损伤患者的药代动力学和安全性。
J Hepatol. 2015 Oct;63(4):805-12. doi: 10.1016/j.jhep.2015.05.029. Epub 2015 Jun 10.
4
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.奥比他韦、帕利瑞韦、利托那韦、达沙布韦联合或不联合利巴韦林治疗丙型肝炎病毒基因型 1 或 4 感染合并肝硬化患者（ABACUS）：一项前瞻性观察研究。
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.
5
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.慢性丙型肝炎病毒（HCV）感染患者中，慢性肾脏病4期、终末期肾病或透析对奥比他韦、帕利瑞韦、利托那韦和达沙布韦血浆浓度的影响：3期RUBY - I和RUBY - II试验的药代动力学分析
Eur J Clin Pharmacol. 2019 Feb;75(2):207-216. doi: 10.1007/s00228-018-2566-6. Epub 2018 Oct 5.
6
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.奥比他韦、帕立瑞韦、利托那韦和达沙布韦联合治疗 8 周，用于初治无肝硬化的 1b 型丙型肝炎病毒感染患者（GARNET）：一项单臂、开放标签、3b 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14.
7
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.帕利瑞韦/利托那韦/奥比他韦/达沙布韦治疗丙型肝炎病毒感染伴晚期肝纤维化血液透析患者的有效性：病例报告。
Am J Kidney Dis. 2017 Aug;70(2):297-300. doi: 10.1053/j.ajkd.2017.01.037. Epub 2017 Mar 1.
8
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.对于近期感染丙型肝炎病毒1型的患者，使用帕利瑞韦/利托那韦/奥米他韦和达沙布韦进行为期八周的缩短疗程治疗具有很高的疗效。
J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8.
9
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.奥美拉唑与丙型肝炎病毒直接作用抗病毒药物帕利瑞韦/利托那韦及奥比他韦合用及与达沙布韦联用时的药物相互作用。
Clin Pharmacol Drug Dev. 2016 Jul;5(4):269-77. doi: 10.1002/cpdd.246. Epub 2016 Jan 24.
10
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.奥比他韦/帕利瑞韦/利托那韦+达萨布韦方案对丙型肝炎患者健康相关生活质量的影响。
Liver Int. 2018 Aug;38(8):1377-1394. doi: 10.1111/liv.13690. Epub 2018 Feb 12.

引用本文的文献

1
Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD.促进丙型肝炎病毒和慢性肾脏病患者围绕直接抗病毒药物治疗时机的以患者为中心的决策制定。
Kidney Med. 2019 Jul 13;1(4):150-152. doi: 10.1016/j.xkme.2019.07.001. eCollection 2019 Jul-Aug.
2
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.直接作用抗病毒药物治疗慢性肾脏病患者慢性丙型肝炎的安全性和疗效。
BMC Nephrol. 2020 Jan 16;21(1):21. doi: 10.1186/s12882-020-1687-1.

本文引用的文献

1
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.奥比他韦/帕利瑞韦/利托那韦治疗丙型肝炎病毒1型或4型感染合并晚期肾病患者的疗效与安全性
Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
2
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.ombitasvir、paritaprevir、利托那韦和达沙布韦联合或不联合利巴韦林用于肾病患者的治疗
Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
3
The Drug-Intoxication Epidemic and Solid-Organ Transplantation.药物中毒流行与实体器官移植
N Engl J Med. 2018 May 17;378(20):1943-1945. doi: 10.1056/NEJMc1802706.
4
Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016.阿片类药物危机对肾脏移植供体库的影响：2010-2016 年全国肾脏死亡供体趋势分析。
Am J Nephrol. 2018;47(2):84-93. doi: 10.1159/000486516. Epub 2018 Feb 13.
5
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.格卡瑞韦和哌仑他韦治疗丙型肝炎病毒合并严重肾功能损害患者。
N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.
6
A Large Outbreak of Hepatitis C Virus Infections in a Hemodialysis Clinic.一家血液透析诊所发生丙型肝炎病毒感染大暴发。
Infect Control Hosp Epidemiol. 2016 Feb;37(2):125-33. doi: 10.1017/ice.2015.247. Epub 2015 Nov 17.
7
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.格拉瑞韦联合艾尔巴韦在初治和经治的丙型肝炎病毒基因型 1 感染和 4-5 期慢性肾脏病患者中的疗效（C-SURFER 研究）：一项联合 III 期研究。
Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5.
8
Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.美国一大群退伍军人中丙型肝炎病毒感染与慢性肾脏病发病率及进展的关联
Hepatology. 2015 May;61(5):1495-502. doi: 10.1002/hep.27664. Epub 2015 Mar 20.
9
Hepatitis C infection is very rarely treated among hemodialysis patients.丙型肝炎感染在血液透析患者中很少得到治疗。
Am J Nephrol. 2013;38(5):405-12. doi: 10.1159/000355615. Epub 2013 Oct 29.
10
Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response.血液透析患者使用干扰素治疗丙型肝炎病毒——个体患者中与持续病毒学应答相关因素的荟萃分析
Clin J Am Soc Nephrol. 2009 Sep;4(9):1449-58. doi: 10.2215/CJN.01850309. Epub 2009 Jul 30.

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function.

作者信息

Sise Meghan E

机构信息

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2018 Dec 1;4(2):191-193. doi: 10.1016/j.ekir.2018.11.018. eCollection 2019 Feb.

DOI:10.1016/j.ekir.2018.11.018
PMID:30775615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6365390/
Abstract
摘要